cas 115010-11-2, 2,3-Dihydro-1-benzofuran-5-sulfonyl chloride

Articles about 115010-11-2Total 29 be found

Article title
Article abstract
Author
Journal number and time
Download

Piperazine adenosine monophosphate activated protein kinase (AMPK) agonist and medical application thereof
The invention discloses a piperazine compound with AMPK agonist activity, and a preparation method and medical application of the piperazine compound. The piperazine compound is a compound shown as aformula (I) (please see the specifications for the formula), and a pharmaceutically acceptable salt or ester or a prodrug or N-oxide or solvate thereof. The compound can be used for preparing drugs for preventing or treating AMPK-mediated diseases.
-
Paragraph 0508; 0510; 0511

(2019/11/12)

BENZOFURAN DERIVED HIV PROTEASE INHIBITORS
Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
-
Page/Page column 12-13

(2008/12/07)

NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS .
The present invention relates to compounds of the general Formula (I), wherein R1, R2 and R3 are as defined in the description; to pharmaceutical compositions comprising these compounds; and to the use of the compounds for
-
Page/Page column 27

(2010/11/08)

Compounds
The present invention relates to compounds of the formula (I), wherein R1 and R2 are as defined in the description; to pharmaceutical formulations comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and/or body weight gain.
-
Page/Page column 3

(2008/06/13)

Resistance-repellent retroviral protease inhibitors
Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
-
Page/Page column 25; 44

(2008/06/13)

NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER
The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.
-
Page/Page column 129

(2010/02/12)

Non-covalent thrombin inhibitors
The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and which feature a six member heterocyclic ring having two ring nitrogen atoms and the remainder of the ring atoms carbon atoms at P1. These compounds have biologic
-
(2008/06/13)

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
-
Page column 48

(2008/06/13)

Sulfonamide inhibitors of aspartyl protease
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
-
Example 180

(2008/06/13)

HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS
Selected heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
-
(2008/06/13)

Bispiperidines as antithrombotic agents
Novel compounds which are inhibitors of the binding of fibrinogen to the Gp IIb/IIIa platelet receptors, and which can be used therepeutically as antithrombotic agents
-
(2008/06/13)

Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
PCT No. PCT/US94/09139 Sec. 371 Date Jan. 24, 1996 Sec. 102(e) Date Jan. 24, 1996 PCT Filed Aug. 23, 1994 PCT Pub. No. WO95/06030 PCT Pub. Date Mar. 2, 1995The invention relates to sulfonamide-containing hydroxyethylamine protease inhibitor compounds, their process of making, composition and method of use for inhibiting retroviral proteases such as human immunodeficiency virus.
-
(2008/06/13)

Synthesis of benzo fused heterocyclic sulfonyl chlorides
A process for preparing a benzo fused heterocyclic sulfonyl halide comprising reacting a benzo fused heterocyclic compound with an SO3 complex in the presence of a water immiscible, non-reactive solvent, at a temperature of from about 0 DEG C. to about 75 DEG C., cooling, if necessary, to a temperature of from about -25 DEG C. to about 65 DEG C. and then adding oxalyl halide.
-
(2008/06/13)

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
-
(2008/06/13)

Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
PCT No. PCT/US96/00607 Sec. 371 Date Feb. 26, 1998 Sec. 102(e) Date Feb. 26, 1998 PCT Filed Jan. 18, 1996 PCT Pub. No. WO96/22287 PCT Pub. Date Jul. 25, 1996Bis-sulfonamido hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to retroviral protease inhibiting compounds of the formula: or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the variables are as defined herein.
-
(2008/06/13)

Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
PCT No. PCT/US96/02685 Sec. 371 Date Jan. 21, 1997 Sec. 102(e) Date Jan. 21, 1997 PCT Filed Mar. 7, 1996 PCT Pub. No. WO96/28464 PCT Pub. Date Sep. 19, 1996Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
-
(2008/06/13)

ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS
-
-
(2008/06/13)

AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS
Described herein is a retroviral protease inhibiting compound of the formula: STR1 or a pharmaceutically acceptable salt, prodrug or ester thereof.
-
(2008/06/13)

SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS
Selected sulfonylalkanoylamino hydroxyethylamine sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
-
(2008/06/13)

Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
Selected sulfonylalkanoylamino hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
-
(2008/06/13)

SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS
Selected sulfonylalkanoylamino hydroxyethylamine sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
-
(2008/06/13)

HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS
Selected heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
-
(2008/06/13)

Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
Selected amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
-
(2008/06/13)

SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
-
(2010/12/01)

ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS
The invention relates to the compounds of formula I STR1 pharmaceutically acceptable prodrug derivatives and pharmaceutically acceptable salts thereof; methods for preparation thereof; pharmaceutical compositions comprising said compounds; and a method of inhibiting matrix-degrading metalloproteinase and of treating matrix-degrading metalloproteinase dependent conditions in mammals using such compounds.
-
(2008/06/13)

ARYLSUFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS
The invention relates to a method of inhibiting metalloellastase activity, of inhibiting the degradation of elastin, or of treating macrophage metalloelastase dependent conditions in mammals which comprises administering to a mammal in need thereof an effective macrophage metalloelastase inhibiting amount of a compound of formula I STR1 wherein Ar, R, R 1 and R. sub.2 have meanings as defined, or of a pharmaceutically acceptable prodrug derivative thereof, or of a pharmaceutically acceptable salt thereof, or of pharmaceutical compositions comprising a said compound.
-
(2008/06/13)

SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
-
(2010/11/30)

Synthesis of bicyclic aromatic sulfonic acids sulfonyl chlorides and sulfonamides
This invention provides a novel process for the synthesis of bicyclic aromatic sulfonic acids employing reacting a bicyclic aromatic compound with sulfur trioxide-N,N-dimethylformamide complex in the presence of a water miscible, non-reactive solvent. The resulting sulfonic acid may be converted into the corresponding sulfonyl halide by the reaction with a thionyl halide. This invention further provides a novel process for the synthesis of bicyclic aromatic sulfonamides employing the reaction conditions described supra followed by an ammonolysis or amination.
-
(2008/06/13)

Arylsulfonamido-substituted hydroxamic acids
Particularly the invention relates to the compounds of formula I STR1 (a) wherein Ar is carbocyclic or heterocyclic aryl; R is hydrogen, lower alkyl, carbocyclic aryl-lower alkyl, carbocyclic aryl, heterocyclic aryl, biaryl, biaryl-lower alkyl, heterocyclic aryl-lower alkyl, mono- or poly-halo-lower alkyl, C3 -C7 -cycloalkyl, C3 -C7 -cycloalkyl-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, amino, mono- or di-lower alkylamino)-lower alkyl, acylamino-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, or (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl; R1 is hydrogen, lower alkyl, carbocyclic aryl-lower alkyl, carbocyclic aryl, heterocyclic aryl, biaryl, biaryl-lower alkyl, heterocyclic aryl-lower alkyl, mono- or poly-halo-lower alkyl, C3 -C7 -cycloalkyl, C3 -C7 -cycloalkyl-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, (carbocyclic or heterocyclic aryl)-lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl, acylamino-lower alkyl, piperidyl or N-lower alkylpiperidyl; R2 is hydrogen or lower alkyl; pharmaceutically acceptable prodrug derivatives; and pharmaceutically acceptable salts thereof.
-
(2008/06/13)

Chemical Properties

Appearance/Colour :UN 3261
Melting Point: 84 °C
Boiling Point: 339.6 °C at 760 mmHg
Flash Point:159.2 °C
Density: 1.495 g/cm³
Solubility:soluble in Toluene
Storage Temp.:0-10°C
Vapor Pressure: 0.000179mmHg at 25°C
Refractive Index: 1.59
PSA: 51.75000
LogP: 2.62980

Global suppliers and manufacturers of 115010-11-2total 50 suppliers on LookChem

Company Name
Business Type
Min Order
FOB Price
Main Products
Contact

Dayang Chem (Hangzhou) Co.,Ltd.
Business Type:Lab/Research institutions
Min Order:1 Kilogram
FOB Price:USD $ 3.0-3.0 / Kilogram
Main Products:994
Country:

Xi'an Xszo Chem Co., Ltd.
Business Type:Manufacturers
Min Order:1 Gram
FOB Price:USD $ 0.1-0.1 / Gram
Main Products:108
Country:

Henan Tianfu Chemical Co., Ltd.
Business Type:Lab/Research institutions
Min Order:1 Kilogram
FOB Price:USD $ 8900.0-8900.0 / Kilogram
Main Products:67
Country:

Zhuozhou Wenxi import and Export Co., Ltd
Business Type:Trading Company
Min Order:1 Kilogram
FOB Price:USD $ 139.0-210.0 / Kilogram
Main Products:1
Country:

Henan Wentao Chemical Product Co., Ltd.
Business Type:Lab/Research institutions
Min Order:No Data
FOB Price:No Data
Main Products:44
Country:

Hangzhou J&H Chemical Co., Ltd.
Business Type:Lab/Research institutions
Min Order:No Data
FOB Price:No Data
Main Products:46
Country:

Hangzhou Huarong Pharm Co., Ltd.
Business Type:Trading Company
Min Order:No Data
FOB Price:No Data
Main Products:65
Country:

Hunan chemfish Pharmaceutical co.,Ltd
Business Type:Manufacturers
Min Order:No Data
FOB Price:No Data
Main Products:29
Country:

Greenutra Resource Inc
Business Type:Trading Company
Min Order:No Data
FOB Price:No Data
Main Products:50
Country:

Kono Chem Co.,Ltd
Business Type:Other
Min Order:No Data
FOB Price:No Data
Main Products:86
Country:

Hangzhou Dingyan Chem Co., Ltd
Business Type:Manufacturers
Min Order:No Data
FOB Price:No Data
Main Products:95
Country:

GIHI CHEMICALS CO.,LIMITED
Business Type:Lab/Research institutions
Min Order:No Data
FOB Price:No Data
Main Products:80
Country:

Shanghai Acmec Biochemical Technology Co., Ltd.
Business Type:Lab/Research institutions
Min Order:1 bottle
FOB Price:No Data
Main Products:30
Country:

Henan Allgreen Chemical Co.,Ltd
Business Type:Manufacturers
Min Order:No Data
FOB Price:No Data
Main Products:34
Country:

Hubei Taiho Chemical Co.,LTD
Business Type:Manufacturers
Min Order:No Data
FOB Price:No Data
Main Products:1
Country:

Antimex Chemical Limied
Business Type:Lab/Research institutions
Min Order:No Data
FOB Price:No Data
Main Products:163
Country:

Hangzhou Fandachem Co.,Ltd
Business Type:Other
Min Order:No Data
FOB Price:No Data
Main Products:52
Country:

Chemlyte Solutions
Business Type:Other
Min Order:No Data
FOB Price:No Data
Main Products:198
Country:

AstaTech ( Chengdu) BioPharmaceutical Corp.
Business Type:Trading Company
Min Order:No Data
FOB Price:No Data
Main Products:43
Country:

Hunan Russell Chemicals Technology Co.,Ltd
Business Type:Trading Company
Min Order:No Data
FOB Price:No Data
Main Products:17
Country:

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 115010-11-2

Article Database

115010-11-2

Articles about 115010-11-2Total 29 be found

More Articles about upstream products of 115010-11-2

More Articles about downstream products of 115010-11-2

Chemical Properties

Appearance/Colour :UN 3261

Melting Point: 84 °C

Boiling Point: 339.6 °C at 760 mmHg

Flash Point:159.2 °C

Density: 1.495 g/cm³

Solubility:soluble in Toluene

Storage Temp.:0-10°C

Vapor Pressure: 0.000179mmHg at 25°C

Refractive Index: 1.59

PSA: 51.75000

LogP: 2.62980

Global suppliers and manufacturers of 115010-11-2total 50 suppliers on LookChem

Article Database

115010-11-2

Articles about 115010-11-2Total 29 be found

More Articles about upstream products of 115010-11-2

More Articles about downstream products of 115010-11-2

Chemical Properties

Appearance/Colour :UN 3261

Melting Point: 84 °C

Boiling Point: 339.6 °C at 760 mmHg

Flash Point:159.2 °C

Density: 1.495 g/cm3

Solubility:soluble in Toluene

Storage Temp.:0-10°C

Vapor Pressure: 0.000179mmHg at 25°C

Refractive Index: 1.59

PSA: 51.75000

LogP: 2.62980

Global suppliers and manufacturers of 115010-11-2total 50 suppliers on LookChem

Density: 1.495 g/cm³